Cerus saw the highest growth of 0.99% in patent filings in May and 1.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 1.99%. GlobalData’s DataBook provides a comprehensive analysis of Cerus’s patent filings and grants. Buy the databook here.
Cerus has been focused on protecting inventions in Israel(IL) with three publications in Q2 2024
The Israel(IL) Patent Office dominates the patent grants with nearly 60% of grants. The United States(US), Israel(IL), and Spain(ES) patent Office are among the top ten patent offices where Cerus is filings its patents. Among the top granted patent authorities, Cerus has 60% of its grants in Israel(IL), 20% in United States(US) and 20% in Spain(ES).
Regeneron Pharmaceuticals and Grifols could be the strongest competitors for Cerus
Patents related to healthtech and smart hospitals lead Cerus's portfolio
Cerus has the highest number of patents in healthtech followed by, smart hospitals and industrial automation. For healthtech, nearly 33% of patents were filed and no patents were granted in Q2 2024.
Sterilisation related patents lead Cerus portfolio followed by hospital supplies, and other remote patient monitoring
Cerus has highest number of patents in sterilisation followed by hospital supplies, other remote patient monitoring, endothelial dysfunction, and shock. For sterilisation, nearly 11% of patents were filed and 25% of patents were granted in Q2 2024.
For comprehensive analysis of Cerus's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.